What drug classes act on Neisseria meningitidis serogroup B surface antigens?

Drug classes acting on Neisseria meningitidis serogroup B surface antigens include Meningococcal serogroup B vaccine, Recombinant protein vaccine, Vaccine.

Neisseria meningitidis serogroup B surface antigens — Drug Target

4 drugs 2 marketed 2 in Phase 3

All drugs that target Neisseria meningitidis serogroup B surface antigens — marketed and clinical-stage. Includes 3 drug classes acting on this target.

Drug classes

Meningococcal serogroup B vaccine · Recombinant protein vaccine · Vaccine

Marketed (2)

rMenB+OMV NZ vaccine · GlaxoSmithKline · Meningococcal serogroup B vaccine · Immunology / Infectious Disease
This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B by combining recombinant meningococcal protein antigens with outer membrane vesicles from a New Zealand strain.
Licensed 4CMenB vaccine · University of Adelaide · Recombinant protein vaccine · Immunology / Infectious Disease
4CMenB is a recombinant meningococcal serogroup B vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B.

Phase 3 pipeline (2)

MenBvac · University Hospital, Rouen · Vaccine · Immunology / Infectious Disease
MenBvac is a meningococcal B vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B.
Meningococcal vaccine GSK134612 · GlaxoSmithKline · Recombinant protein vaccine · Immunology / Infectious Disease
This vaccine stimulates the immune system to produce antibodies against meningococcal serogroup B antigens, providing protection against meningococcal disease.